Shanghai Haoyuan Chemexpress Co., Ltd.

Shanghai Stock Exchange 688131.SS

Shanghai Haoyuan Chemexpress Co., Ltd. Revenue for the year ending December 31, 2023: USD 264.80 M

Shanghai Haoyuan Chemexpress Co., Ltd. Revenue is USD 264.80 M for the year ending December 31, 2023, a 34.56% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Shanghai Haoyuan Chemexpress Co., Ltd. Revenue for the year ending December 31, 2022 was USD 196.80 M, a 29.02% change year over year.
Shanghai Haoyuan Chemexpress Co., Ltd. Revenue for the year ending December 31, 2021 was USD 152.54 M, a 56.77% change year over year.
Shanghai Haoyuan Chemexpress Co., Ltd. Revenue for the year ending December 31, 2020 was USD 97.30 M, a 65.67% change year over year.
Shanghai Haoyuan Chemexpress Co., Ltd. Revenue for the year ending December 31, 2019 was USD 58.73 M, a 34.55% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 688131.SS

Shanghai Haoyuan Chemexpress Co., Ltd.

CEO	Mr. Baofu Zheng
IPO Date	June 8, 2021
Location	China
Headquarters	No. 3 Building, No. 1999
Employees	3,370
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials

Description

Shanghai Haoyuan Chemexpress Co., Ltd. researches and develops pharmaceutical intermediates and small molecule drugs. It manufactures APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.

Key trends

Past 5 years